HIV vaccine trials: some design issues including sample size calculation

Area of Science:

• Clinical Trials
• Vaccinology
• Epidemiology

Background:

• Anticipation of candidate human immunodeficiency virus (HIV) vaccines for efficacy testing.
• Public health agencies are planning large-scale efficacy trials for HIV vaccines.

Purpose of the Study:

• To discuss factors influencing sample size calculations for HIV vaccine efficacy trials.
• To determine the necessary participant numbers for statistically significant trial outcomes.

Main Methods:

• Analysis of factors impacting sample size, including HIV incidence and minimum acceptable vaccine efficacy.
• Modeling of trial duration, benefit accrual, assay accuracy, participant counseling, and loss to follow-up.
• Calculation of sample sizes under varying efficacy and incidence scenarios.

Main Results:

• Sample size is highly sensitive to HIV incidence rates and the minimum acceptable vaccine efficacy.
• Detecting 90% efficacy with 7% annual HIV risk requires 83 subjects per arm (3-year study).
• Detecting 60% efficacy with 1% annual HIV risk requires 4,254 subjects per arm (2-year study with 5% loss to follow-up).

Conclusions:

• Realistic assumptions indicate that HIV vaccine efficacy trials will likely require several thousand participants.
• Careful consideration of statistical power, ethical considerations, and logistical factors is crucial for trial design.